Dicerna Pharmaceuticals (DRNA) Price Target Raised to $26.00 at SunTrust Banks

Dicerna Pharmaceuticals (NASDAQ:DRNA) had its price target hoisted by analysts at SunTrust Banks to $26.00 in a note issued to investors on Wednesday, The Fly reports. The brokerage presently has a “buy” rating on the biopharmaceutical company’s stock. SunTrust Banks’ target price would suggest a potential upside of 111.21% from the stock’s previous close.

A number of other equities analysts have also recently issued reports on the stock. Zacks Investment Research upgraded shares of Dicerna Pharmaceuticals from a “hold” rating to a “buy” rating and set a $13.00 price target on the stock in a research note on Tuesday. BidaskClub cut shares of Dicerna Pharmaceuticals from a “buy” rating to a “hold” rating in a research note on Tuesday. Cowen assumed coverage on shares of Dicerna Pharmaceuticals in a research note on Tuesday, February 26th. They issued an “outperform” rating on the stock. ValuEngine cut shares of Dicerna Pharmaceuticals from a “hold” rating to a “sell” rating in a research note on Monday, February 25th. Finally, Chardan Capital upgraded shares of Dicerna Pharmaceuticals from a “neutral” rating to a “buy” rating and set a $18.00 price target on the stock in a research note on Tuesday, January 22nd. One analyst has rated the stock with a sell rating, two have issued a hold rating and nine have issued a buy rating to the company. Dicerna Pharmaceuticals currently has an average rating of “Buy” and an average price target of $21.78.

Shares of Dicerna Pharmaceuticals stock opened at $12.31 on Wednesday. The stock has a market capitalization of $720.16 million, a P/E ratio of -10.26 and a beta of 2.40. Dicerna Pharmaceuticals has a 1 year low of $8.71 and a 1 year high of $17.98.

Dicerna Pharmaceuticals (NASDAQ:DRNA) last announced its quarterly earnings results on Monday, March 11th. The biopharmaceutical company reported ($0.29) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($0.23) by ($0.06). The firm had revenue of $1.54 million during the quarter, compared to the consensus estimate of $8.38 million. Dicerna Pharmaceuticals had a negative return on equity of 65.91% and a negative net margin of 1,438.68%. On average, analysts expect that Dicerna Pharmaceuticals will post -0.66 earnings per share for the current year.

A number of large investors have recently modified their holdings of the business. RTW Investments LP raised its position in Dicerna Pharmaceuticals by 8.2% in the 4th quarter. RTW Investments LP now owns 5,907,088 shares of the biopharmaceutical company’s stock worth $63,147,000 after buying an additional 445,964 shares during the last quarter. BlackRock Inc. raised its position in Dicerna Pharmaceuticals by 46.0% in the 4th quarter. BlackRock Inc. now owns 4,331,228 shares of the biopharmaceutical company’s stock worth $46,300,000 after buying an additional 1,364,155 shares during the last quarter. EcoR1 Capital LLC raised its position in Dicerna Pharmaceuticals by 28.4% in the 3rd quarter. EcoR1 Capital LLC now owns 3,802,327 shares of the biopharmaceutical company’s stock worth $58,024,000 after buying an additional 841,180 shares during the last quarter. Vanguard Group Inc. raised its position in Dicerna Pharmaceuticals by 40.7% in the 3rd quarter. Vanguard Group Inc. now owns 1,983,272 shares of the biopharmaceutical company’s stock worth $30,265,000 after buying an additional 573,197 shares during the last quarter. Finally, Vanguard Group Inc raised its position in Dicerna Pharmaceuticals by 40.7% in the 3rd quarter. Vanguard Group Inc now owns 1,983,272 shares of the biopharmaceutical company’s stock worth $30,265,000 after buying an additional 573,197 shares during the last quarter. 92.81% of the stock is owned by institutional investors and hedge funds.

Dicerna Pharmaceuticals Company Profile

Dicerna Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the discovery and development of ribonucleic acid interference (RNAi)-based pharmaceuticals. The company develops pharmaceuticals using its GalXC RNAi platform for the treatment of diseases involving the liver, including rare diseases, viral infectious diseases, chronic liver diseases, and cardiovascular diseases.

Recommended Story: Bollinger Bands

The Fly

Analyst Recommendations for Dicerna Pharmaceuticals (NASDAQ:DRNA)

Receive News & Ratings for Dicerna Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Dicerna Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.